Third trial over Zantac cancer claims ends with hung jury
Adds response from plaintiff's attorney in paragraphs 2-3
By Brendan Pierson
Aug 7 (Reuters) -The third trial over claims that discontinued heartburn drug Zantac ended in a mistrial on Wednesday when jurors could not agree about whether pharmaceutical companyBoehringer Ingelheim was responsible for an Illinois man's cancer.
Martin Gross alleged in his lawsuit in state court in Chicago that he developed prostate cancer from a carcinogenic contaminant called NDMA found in the drug. His lawyer,Sean Grimsley, said he would take his case to trial again.
"We continue to believe in our case, in our cause and in our client," he said.
Boehringer Ingelheim said in a statement that it was "disappointed" that the jury had not reached a verdict and that "the totality of the scientific evidence" supports "only one conclusion: Zantac does not cause any type of cancer."
First approved by U.S. regulators in 1983, Zantac became the world's best-selling medicine in 1988 and one of the first to top $1 billion in annual sales. It was sold at different times by Boehringer Ingelheim, GSK GSK.L, Pfizer PFE.N and Sanofi SASY.PA, all of which have faced thousands of lawsuits.
Two such cases previously went to trial, both ending in verdicts for the defense - one for Boehringer Ingelheim and GSK in May, and the other for GSK on Monday.
Sanofi has agreed to settle about 4,000 cases against it, while Pfizer has reportedly agreed to settle more than 10,000. The companies have also settled some individual cases before trial.
The majority of the lawsuits are in Delaware state court, where a judge in June allowed more than 70,000 cases to go forward after rejecting the defendants' bid to keep key plaintiffs' expert witnesses out of court on the grounds that their scientific methods were not reliable. The companies are appealing that ruling.
The litigation began after the U.S. Food and Drug Administration in 2020 asked manufacturers to pull the drug off the market over concerns that ranitidine, the active ingredient in Zantac and generic versions of the drug, could degrade into NDMA over time or when exposed to heat.
The drugmakers have said the cases are meritless. They won a significant victory in 2022, when a Florida federal judge ruled against about 50,000 cases, finding that the alleged cancer link was not supported by sound science. Some of those cases are being appealed.
Reporting By Brendan Pierson in New York; Editing by Aurora Ellis and Diane Craft
Activos relacionados
Últimas noticias
Descargo de responsabilidades: Cada una de las entidades de XM Group proporciona un servicio de solo ejecución y acceso a nuestra plataforma de trading online, permitiendo a una persona ver o usar el contenido disponible en o a través del sitio web, sin intención de cambiarlo ni ampliarlo. Dicho acceso y uso están sujetos en todo momento a: (i) Términos y Condiciones; (ii) Advertencias de riesgo; y (iii) Descargo completo de responsabilidades. Por lo tanto, dicho contenido se proporciona exclusivamente como información general. En particular, por favor tenga en cuenta que, los contenidos de nuestra plataforma de trading online no son ni solicitud ni una oferta para entrar a realizar transacciones en los mercados financieros. Operar en cualquier mercado financiero implica un nivel de riesgo significativo para su capital.
Todo el material publicado en nuestra plataforma de trading online tiene únicamente fines educativos/informativos y no contiene –y no debe considerarse que contenga– asesoramiento ni recomendaciones financieras, tributarias o de inversión, ni un registro de nuestros precios de trading, ni una oferta ni solicitud de transacción con instrumentos financieros ni promociones financieras no solicitadas.
Cualquier contenido de terceros, así como el contenido preparado por XM, como por ejemplo opiniones, noticias, investigaciones, análisis, precios, otras informaciones o enlaces a sitios de terceros que figuran en este sitio web se proporcionan “tal cual”, como comentarios generales del mercado y no constituyen un asesoramiento en materia de inversión. En la medida en que cualquier contenido se interprete como investigación de inversión, usted debe tener en cuenta y aceptar que dicho contenido no fue concebido ni elaborado de acuerdo con los requisitos legales diseñados para promover la independencia en materia de investigación de inversiones y, por tanto, se considera como una comunicación comercial en virtud de las leyes y regulaciones pertinentes. Por favor, asegúrese de haber leído y comprendido nuestro Aviso sobre investigación de inversión no independiente y advertencia de riesgo en relación con la información anterior, al que se puede acceder aquí.
